Chinese biopharma company making biologics including erythropoietin (EPO) and other injectable drugs, parent of Sunshine Guojian.
Chinese biopharma company making biologics including erythropoietin (EPO) and other injectable drugs, parent of Sunshine Guojian.
Sells legacy biologics such as TPIAO, a platelet-boosting drug, and EPO through hospitals in China, and these long-established products carry current earnings. Out-licensing is the newer line: in 2025 it gave Pfizer rights outside China to a cancer antibody drug in exchange for upfront and milestone payments.
In one line: A Chinese Amgen-scale biologics maker.
Moat: narrow (scale, IP / patents, distribution). Established hospital distribution for legacy biologics plus a growing biosimilar/innovative pipeline via its subsidiary.
Headquarters: Shenyang, China · Founded: 1993 · Employees: 6,109
Size 3SBio (1530.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $4.28B, the 275th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$13.30 on 18 Nov 2026.
Performance Over six months the shares fell 31.1%, against +2.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 101.7% over the last twelve months (peer median -6.4%); the operating margin is 60.6% (peer median -35.0%).
Valuation It trades at 12.0× forward earnings against a peer median of 31.7× (cheapest of 7).
Capital Return on invested capital runs 39.3 points above its cost of capital (9.3% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$19.8B | HK$19.2B | HK$9.88B | HK$8.64B | HK$7.98B |
| Revenue growth | — | +94% | +14% | +8% | — |
| Gross profit | HK$18.2B | HK$17.7B | HK$8.49B | HK$7.34B | HK$6.60B |
| EBITDA | HK$12.6B | HK$12.0B | HK$3.31B | HK$3.02B | HK$2.72B |
| Net income | HK$9.11B | HK$9.20B | HK$2.27B | HK$1.71B | HK$2.23B |
| Free cash flow | HK$10.2B | HK$10.2B | HK$3.10B | HK$1.58B | HK$1.56B |
| Capital expenditure | HK$744M | HK$587M | HK$1.04B | HK$778M | HK$1.13B |
| Total debt | n/a | HK$2.92B | HK$3.78B | HK$5.33B | HK$5.07B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| 3SBio 1530.HK | $4.28B | -31% | +102% | 61% | 12.0× | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% |
| Cspc Pharma 1093.HK | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Shanghai Henlius Biotech 2696.HK | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1530.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.5% | -5.3% | 9th lowest of 21 |
| 6-month return | -31.1% | +2.0% | 2nd lowest of 21 |
| Distance from 52-week high | -62.5% | -33.1% | lowest of 21 |
| Revenue growth (TTM) | +101.7% | -6.4% | highest of 17 |
| Operating margin | 60.6% | -35.0% | highest of 16 |
| Forward P/E | 12.0× | 31.7× | cheapest of 7 |
| ROIC minus cost of capital | +39.3 pp | -15.3 pp | highest of 15 |
| EV / EBITDA | 1.5× | n/a | — |
| Net debt / EBITDA | -1.5× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 12.0× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 30.3× | 32.4% | +7.1% |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 12.8× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | n/a | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $4.75B | 0% | +22% | 10% | 59.8× | 25.4% | +15.6% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 14.4× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | n/a | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | n/a | -6.5% | -10.0% |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% | +12.5% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 64.3× | 36.9% | +26.2% |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |